NEW YORK ( TheStreet) -- Santarus (Nasdaq: SNTS) hit a new 52-week high Friday as it is currently trading at $6.28, above its previous 52-week high of $6.25 with 94,584 shares traded as of 1:13 p.m. ET. Average volume has been 414,100 shares over the past 30 days. Santarus has a market cap of $371.7 million and is part of the health care sector and drugs industry. Shares are up 87.9% year to date as of the close of trading on Thursday. Santarus, Inc., a specialty biopharmaceutical company, engages in acquiring, developing, and commercializing proprietary products that address the needs of patients treated by physician specialists. The company has a P/E ratio of 86.7, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7.
TheStreet Ratings rates Santarus as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. You can view the full Santarus Ratings Report. See all 52-week high stocks or get investment ideas from our investment research center.